ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1228

Trabecular BONE Score In Rheumatoid Arthritis and Ankylosing Spondylitis and Changes During LONG TERM Treatment With TNFA Blocking Agents

Eric Toussirot1, Laurent Mourot2, Daniel Wendling3, Gilles Dumoulin4 and CIC BT5, 1Université de Franche Comté , CHRU, CIC Biotherapy 506 and Rheumatology and EA 4266 Pathogens and Inflammation, Besançon, France, 2CIC-It, University of Franche Comté, Besançon, France, 3Rheumatology, University Hospital, Besancon, France, 4University hospital, Department of Endocrine and Metabolic Biochemistry, Besançon, France, 5CIC BT, University Hospital, Besançon, France

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Dual energy x-ray absorptiometry (DEXA), rheumatoid arthritis (RA) and spondylarthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Osteoporosis and Metabolic Bone Disease: Clinical Aspects and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Inflammatory rheumatic diseases such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are associated with osteoporosis. Bone mass in RA and AS has been well evaluated by measuring areal bone mineral density (BMD) with DXA. Trabecular bone score (TBS) is a new method evaluating bone microarchitecture by assessing pixel gray- level variations in DXA images from lumbar spine.

Objectives: In a case-control study, TBS was evaluated in patients with RA or AS and healthy controls (HC) and the results were compared to lumbar spine (LS) BMD measurements. Changes in LS and hip BMD and TBS score after initiating and during long term anti-TNFa treatment were also examined in a prospective study.

Methods:

– In the case control study, 30 patients with RA (ACR criteria, 19 F; 12 post menopausal women; age [mean ± SD]: 56.9 ± 9.7 yrs; disease duration: 11.7 ± 8.8 yrs; 26 under low dosage corticosteroids [CTC]) and 30 patients with AS (modified NY criteria, 27 M, age 43.8 ± 13.4 yrs; disease duration: 13.0 ± 11.1 yrs; no CTC) were evaluated and compared to 50 HC (29 F, 12 post menopausal women, age: 46.6 ± 11.1 yrs). L2-L4 BMD and hip BMD were measured using DXA (Lunar GE iDXA). TBS was calculated from L2-L4 BMD images (TBS insight®, Med-Imaps).

– In the prospective study, a group of 20 patients requiring TNFa blocking agent (6 F; 12 AS, [age: 40.7 ± 16.1 yrs] and 8 RA [age 60.5 ± 9.7 yrs]; disease duration: 9.6 ± 9.8 yrs; 9 under low dose CTC) were followed for 2 years. LS BMD, hip BMD and TBS score were measured at baseline and after 6, 12 and 24 months of treatment.

Results:

– Case control study: RA patients had lower BMD and T score at the hip (p < 0.005) compared to HC. Hip T score in patients with AS was also decreased (p = 0.02). LS BMD did not differ between patients and HC. TBS was lower in RA and AS compared to HC: 1.242 ± 0.16 and 1.282 ± 0.13 vs 1.365 ± 0.14, respectively (p= 0.005).

– Prospective study: under anti-TNFa, LS and hip BMD at M24 increased (+ 6.3% and + 2.4% respectively), with significant changes at the spine (p< 0.001). In the whole group, TBS score slightly increased from baseline to M12 (1,304 ± 0.13 to 1.32 ± 0.09) without significance, then returning to initial values at M24 (1.309 ± 0.09). However, in patients with RA, TBS score decreased (baseline to M24: 1.362 ± 0.048 to 1.308 ± 0.07) (p = 0.032) while in patients with AS, TBS progressively increased (1.257 ± 0.15 vs 1.309 ± 0.11; NS).

Conclusion: TBS score is decreased in inflammatory rheumatic diseases, especially in RA, suggesting alterations of bone micro architecture. Long term anti TNFa treatment is associated with a positive effect on (LS) bone mass but no major changes in TBS score. Surprisingly and on the contrary of AS, TBS score decreased in RA treated by TNFa blocking agents, suggesting different influences and responses of the bone to this drug’s class.


Disclosure:

E. Toussirot,
None;

L. Mourot,
None;

D. Wendling,
None;

G. Dumoulin,
None;

C. BT,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/trabecular-bone-score-in-rheumatoid-arthritis-and-ankylosing-spondylitis-and-changes-during-long-term-treatment-with-tnfa-blocking-agents/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.